SK Biopharmaceuticals Signs 48.3 Billion Won Pharmaceutical Supply Contract
On the 24th, SK Biopharmaceuticals announced that it had signed a pharmaceutical supply contract worth 48.3 billion won with its U.S. subsidiary, SK Life Science. This amount is equivalent to 8.8% of its 2024 consolidated sales of 547.6 billion won.
The contract is for supplying products to the subsidiary for the sale of cenobamate, a new antiepileptic drug, in the U.S. market. Because the counterparty is a subsidiary, the transaction is an internal one and will not be reflected as revenue in the consolidated financial statements.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
The contract period runs from the 24th through the 26th.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.